Benralizumab not effective reducing exacerbations in moderate to very severe COPD

New research shows that the asthma drug benralizumab failed to decrease annual COPD exacerbation rates for patients with moderate to very severe COPD, a history of frequent moderate and/or severe exacerbations, and eosinophilic inflammation. Lesen Sie weiter auf: Benralizumab not effective reducing exacerbations in moderate to very severe COPD Quelle: ScienceDaily | Asthma Titelbild/Grafik by […]

…/Auszug